---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-130002"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T00:55:05.655516+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics: 78% objective response in APOLLO study; raises $16.1M in private placement

## Summary
- Phase 1 APOLLO: 78% of patients (7/9) achieved objective response; 44.4% complete response at first assessment.
- MT-601 well tolerated; no ICANS observed, one Grade 1 CRS; no dose-limiting toxicities.
- Private placement raises $16.1M gross proceeds; 5,031,250 shares at $3.20 with warrants at $4.03.
- Proceeds to support clinical advancement of MT-601 in relapsed lymphoma after CAR-T failure.
- New and existing investors: Blue Owl, NEA, and Aisling Capital participated in the financing.

## SEC filing metadata
- accession: 0001104659-24-130002
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465924130002/0001104659-24-130002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465924130002/tm2431560d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-130002
- JSON: https://secwatch.observer/filing/0001104659-24-130002.json
- Plain text: https://secwatch.observer/filing/0001104659-24-130002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.